Genetic tools have been developed to efficiently engineer T-cell specificity and enhance T-cell function. Chimeric antigen receptors (CAR) use the antibody variable segments to direct specificity against cell surface molecules. T-cell receptors (TCR) can redirect T cells to intracellular target proteins, fragments of which are presented in the peptide-binding groove of HLA molecules. A recent clinical trial with CAR-modified T cells redirected against the B-cell lineage antigen CD19 showed dramatic clinical benefit in chronic lymphocytic leukaemia patients. Similarly, impressive clinical responses were seen in melanoma and synovial cell carcinoma with TCR-modified T cells redirected against the melanocyte lineage antigen MART-1 and the testis-cancer antigen NY-ESO-1. However, on and off-target toxicity was associated with most of these clinical responses, and fatal complications have been observed in some patients treated with gene modified T cells. This review will discuss factors that might contribute to toxic side effects of therapy with gene modified T cells, and outline potential strategies to retain anticancer activity while reducing unwanted side effects.
EFFICACY OF IMMUNOTHERAPY WITH NON-GENE MODIFIED T CELLS
Allogeneic stem cell transplantation is a curative treatment for patients with leukaemia and lymphoma. The curative potential is strictly dependent on the administration of allogeneic T cells, as T-cell depletion resulted in a high risk of leukaemia relapse in transplanted patients. 1 The efficacy of allogeneic T-cell therapy is due to the targeting of immunogenic minor and major histocompatibility antigens that stimulate potent T-cell responses. 2, 3 However, the expression of these histocompatibility antigens on normal tissues can result in a life threatening complication of allogeneic T-cell therapy in the form of severe graft versus host disease. Improving the specificity of allogeneic T-cell therapy by selecting immunogenic antigens that are primarily expressed in patients leukaemia cells, but absent in non-haematopoietic tissues, has been a major focus of research in the past years. 4 Adoptive transfer of autologous tumour-infiltrating lymphocytes (TIL) is another example of effective immunotherapy of cancer. To date, this approach has been largely limited to the treatment of melanoma where more than 50% of patients experience a partial or complete regression of clinically advanced stage III-IV cancer. 5 Initial trials involving adoptive transfer of in vitro expanded T-cell clones showed poor T-cell engraftment and persistence, associated with little anti-melanoma activity. However, pre-treatment of patients with lympho-depleting conditioning dramatically improved the level of T-cell engraftment and enhanced anti-tumor activity. 6 These observations in melanoma provided a rationale for the use of lympho-depleting conditioning in the majority of adoptive T-cell therapy studies performed in the past few years.
A further example of successful adoptive T-cell therapy is the transfer of virus-specific T cells into transplanted patients. Owing to the transplant-related immunosuppression, these patients are unable to efficiently control latent viral pathogens, such as cytomegalovirus (CMV) and Epstein Barr virus (EBV), and are therefore at high risk of developing CMV disease and EBV-driven lymphoproliferation. Clinical trials have clearly demonstrated that the infusion of relatively small numbers of CMV-or EBV-specific T cells is effective in controlling CMV viral load and preventing post-transplant lymphoproliferation. 7, 8 Together, the results with 'conventional' T-cell therapies indicate the curative potential of this type of treatment. The potential side effects of allogeneic T-cell therapy highlight the importance of specific targeting of tumour-associated or tumourspecific antigens. Although conditioning can improve anti-tumour activity, the lympho-depleting treatment increases the side effect spectrum of adoptive T-cell therapy. Finally, the results with CMV and EBV infection in transplant patients indicate that relatively small T-cell doses can be clinically effective. In this setting clinical efficacy is achieved without 'active' lympho-depletion conditioning.
T-CELL ENGINEERING
The production of antigen-specific T-cell populations has remained a major challenge for adoptive immunotherapy of cancer and chronic viral infection. Virus-specific T cells can only be isolated from latently infected donors with detectable T-cell responses, and the production of therapeutic TIL populations fails in 30-50% of melanoma patients and has not yet been successful in other malignancies.
However, in the past years T-cell engineering has provided solutions by demonstrating that retroviral and lentiviral gene transfer can reliably generate therapeutic T-cell populations of defined antigen-specificity. Both, the transfer of antibody-based chimeric antigen receptors (CARs) or the transfer of T-cell receptors (TCR) is an efficient strategy to redirect polyclonal human T cells to well-defined tumour-associated target antigens. [9] [10] [11] Thus, monoclonal CAR and TCR have become generic therapeutics for the treatment of malignancies expressing the relevant CAR or TCR-recognised target antigens, and in the case of TCR the restricting HLA molecules required for antigen presentation. Although the first-generation CAR constructs containing only the CD3-zeta or FcR-gamma signalling modules were unable to efficiently promote proliferation, survival and persistence of adoptively transferred T cells, this limitation was overcome by the development of second-generation CAR containing additional co-stimulatory signalling modules of CD28, 41BB, OX40 and others. 12 The optimal combination of signalling modules is currently being researched and is likely to be dependent on immune-modulatory factors in a tumour microenvironment, and on whether the T cells are transferred into nonconditioned or lympho-depleted patients.
The introduction of therapeutic TCR into polyclonal human T cells can lead to the formation of mixed alpha/beta dimers between the introduced and the endogenous TCR chains. 13 This can reduce the expression levels of therapeutic TCR alpha/beta combinations on the surface of the engineered T cells, which in turn can reduce the ability of these cells to respond to low concentrations of antigen. In addition, the mixed alpha/beta dimers create novel specificities, including potentially autoreactive specificities, which can cause toxicity as recently demonstrated in murine model experiments. 14 Various strategies have been developed to reduce or eliminate the risk of mixed dimer formation. This includes modification of the protein sequence of the therapeutic TCR chains to reduce pairing with endogenous TCR, [15] [16] [17] the production of single-chain TCR constructs 18 and the knockdown of endogenous TCR expression using shRNA technologies and zinc-finger nucleases. 19, 20 Although sequence-modified TCR have already been used in clinical trials, to date single-chain TCR and knockdown technologies have been limited to preclinical studies.
CLINICAL RESULTS WITH ENGINEERED T CELLS
Recent clinical trials with a CAR construct specific for CD19 have shown dramatic clinical results in patients suffering from chronic lymphocytic leukaemia. 21, 22 In contrast, the clinical benefits of treatment with a different CAR construct targeting CD19 were much less impressive. 23 Although the reason for this difference is not entirely understood, the molecular composition of the CAR configuration may have an important role. The CAR combination containing the CD3 zeta signalling module together with 4-1BB was associated with strong anti-leukaemia activity, large in vivo expansion and high levels of T-cell persistence, whereas these parameters were reduced with the CAR construct containing CD3 zeta together with the CD28 signalling module. In addition to differences in the signalling modules, the CARs also differed in the fine specificity of the anti-CD19 antibodies used to generate the CARs. Thus, differences in the affinity for the CD19 epitope recognised by the CAR may affect function, as previously demonstrated with affinity-matured CAR constructs. 24 Impressive clinical responses were also recently demonstrated in trials using a TCR specific for NY-ESO-1, a testis-cancer antigen that is normally silent in most tissues but active in a large number of malignancies. The adoptive transfer of NY-ESO-1 TCR-modified T cells resulted in tumour regression in patients with melanoma and synovial cell carcinoma. 25 Interestingly, the TCR used in this study was mutated in vitro to enhance its affinity for the NY-ESO-1 peptide presented by HLA-A0201 molecules. This in vitro affinity maturation improved TCR function without increasing TCR crossreactivity. Although the technology for in vitro TCR affinity maturation is now well established, it is becoming clear that enhancement from the ''normal''-affinity range (Kd 1-100 mM) to the ''high''-affinity range (o1 nM) normally seen with antibodies probably impairs T-cell function in two ways. First, T cells expressing high-affinity TCR require higher antigen concentration to trigger effector function compared with T cells expressing 'normal'-affinity TCR. 26 At low antigen concentration serial TCR triggering is essential, and stable high-affinity interactions with long half-life prevent one peptide/HLA complex from sequential binding and stimulation of multiple TCR molecules. 27, 28 Second, high-affinity TCR have an increased risk of cross-reactivity. Paradoxically, owing to improved serial TCR triggering, lowaffinity cross-reactive interactions may stimulate T-cell activation more efficiently than the stable long-lived interactions between an affinity-matured TCR and the cognate HLA/peptide complex.
TOXIC SIDE EFFECTS
The side effects observed in the setting of adoptive therapy with gene-engineered T cells can be described in three major categories: (i) on-target toxicity is due to the expression of the CAR-or TCR-recognised target antigen in normal tissues; (ii) offtarget toxicity results in damage of tissues and organs that do not express the CAR-or TCR-recognised antigen; (iii) conditioning toxicity is due to side effects of the lympho-depleting treatment used to facilitate the engraftment of the adoptively transferred T cells.
On-target toxicity was seen with a TCR specific for the melanoma-associated antigen MART-1, which is also expressed in pigmented tissues and normal melanocytes. Following transfer of MART-1 TCR-engineered T cells, patients developed skin rash, hearing loss and unveitis, which is consistent with the antigenspecific damage of these tissues with known MART-1 expression. 29 On-target toxicity was also seen with a TCR specific for a CEA peptide presented by HLA-A0201. The physiological CEA expression in the colon explains the inflammatory colitis that occurred in patients treated with CEA-TCR-engineered T cells. 30 Finally, the elimination of the normal B-cell compartment in patients treated with anti-CD19 CAR-engineered T cells represents an expected ontarget toxicity requiring immunoglobulin replacement therapy for CAR-treated patients. 21, 31 However, the cardiac toxicity described in a patient treated with anti-CD19 CAR-engineered T cells is unlikely to be due to CD19 expression in the heart tissue and represents a form of off-target toxicity. 21, 31 Following adoptive T-cell therapy, elevated levels of inflammatory cytokines, such as IFNg, TNFa and IL6, have been found in the serum of patients, which probably causes systemic toxicity, including cardiac arrhythmia that has been observed in patients treated with recombinant IL6. 32 Another form of offtarget toxicity is caused by the mis-pairing of therapeutic TCR chains with the endogenous TCR chains present in the genemodified T cells. 14 The specificity of the mis-paired TCR combinations is not predictable, but can contain auto-reactive specificities that can cause extensive damage of normal tissues. Such auto-toxicity of TCR-engineered T cells has been clearly demonstrated in murine models, but not yet in humans.
Two recent trials with CAR-engineered T cells reported serious adverse effects associated with a fatal outcome. In one study, the CAR specificity was directed against human epithelial growth factor receptor 2 (ErbB-2, Her2, CD340); the adoptive transfer of CAR-engineered T cells led to pulmonary toxicity, cytokine storm and multi-organ failure, a series of events that were probably triggered by low-level ErbB-2 expression in the lung epithelial cells. 33 The second fatal complication was reported in a patient treated with anti-CD19 CAR-modified T cells. In this case, T-cell infusion was associated with an increase in serum levels of phosphorus, potassium and uric acid, which is compatible with a tumour lysis syndrome. The cause of death in this patient remained unclear, and may have been due to infection unrelated to the T-cell transfer. 34 Fludarabine in combination with cyclophosphamide is most frequently used to pre-treat patients before the infusion of genemodified T cells. This lympho-depleting, non-myeloablative regimen is based on the observation that it substantially improved the efficacy of adoptive therapy with tumour-infiltrating lymphocytes in melanoma patients, although it was associated with toxic side effects. 6 Although there is evidence that more agressive conditioning may further increase the efficacy of adoptive T-cell therapy, it also increases the toxicity of the conditioning protocol. 5 
REDUCTION OF TOXICITY
The clinical trials to date suggest that on-target toxicity represents a substantial problem of adoptive therapy with gene-modified T cells. The targeting of tumour markers that are absent from normal tissues is a strategy to retain anti-tumour activity without normal tissue damage. There are two categories of tumourspecific antigens for selective tumour attack: (i) viral antigens in human cancers caused by transforming viruses; (ii) mutated proteins that arise in cancers due to genome instability. CAR and TCR specific for viral and mutated-tumour antigens are expected to mediate tumour immunity without on-target toxicity in normal tissues.
Off-target toxicity due to CAR or TCR cross-reactivity is a chance event and is difficult to control. However, artificial maturation of TCR affinity beyond its natural range increases the risk of crossreactive recognition of unrelated antigens, thus increasing the risk of off-target toxicity.
The inclusion of suicide switches into the vectors used to engineer T cells provides an additional safety net when infused T cells cause unexpected toxicities. In recent years a number of suicide switches have been developed, and the capase switch has been shown to efficiently eliminate T cells in patients. 35, 36 Finally, the production of therapeutic T cells that can provide protective immunity in non-conditioned patients will be a major step forward. Avoiding the toxicity of conditioning would decrease the side effect profile of adoptive T-cell therapy. In fact, relatively small numbers of virus-specific T cells can control CMV infection and EBV lymphoproliferation in the absence of patient conditioning before T-cell infusion. This indicates that functionally competent T cells with the appropriate specificity can have therapeutic efficacy in non-conditioned patients. There is a possibility that the targeting of truly tumour-specific antigens by the appropriate naïve or memory T-cell subset may provide a platform for adoptive T-cell therapy that no longer requires lympho-depleting conditioning of patients.
